Selpercatinib

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H31N7O3
Molecular Weight	525.6015
Optical Activity	NONE
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(CN2C3CC2CN(C3)C4=NC=C(C=C4)C5=CC(OCC(C)(C)O)=CN6N=CC(C#N)=C56)C=N1

InChI

InChIKey=XIIOFHFUYBLOLW-UHFFFAOYSA-N

InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C29H31N7O3
Molecular Weight	525.6015
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf | https://www.loxooncology.com/docs/presentations/2016_EORTC_LOXO-292_POSTER.pdf

Selpercatinib (LOXO-292, ARRY-192) is a potent and specific RET (c-RET) inhibitor that was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Proto-oncogene tyrosine-protein kinase receptor Ret 7 Target ID: P07949 Gene ID: 5979.0 Gene Symbol: RET Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Inhibitor 8504		0.56 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
RET fusion-positive non-small cell lung cancer 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Primary	Approved 8583	RETEVMO Approved Use RETEVMO is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)1. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
RET fusion-positive thyroid cancer 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Primary	Approved 8583	RETEVMO Approved Use RETEVMO is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)1. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
RET-mutant medullary thyroid cancer 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Primary	Approved 8583	RETEVMO Approved Use RETEVMO is a kinase inhibitor indicated for the treatment of: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)1. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)

C_max

Value	Dose	Co-administered	Analyte	Population
3287 ng/mL EXPERIMENT https://pdfs.semanticscholar.org/cfc8/3d2a1480f8c2009538a722390a58679b3f6b.pdf	160 mg 2 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:		SELPERCATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2980 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	160 mg 2 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SELPERCATINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
21753 ng × h/mL EXPERIMENT https://pdfs.semanticscholar.org/cfc8/3d2a1480f8c2009538a722390a58679b3f6b.pdf	160 mg 2 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SELPERCATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
51600 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	160 mg 2 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SELPERCATINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
10000 ng × h/mL EXPERIMENT https://pdfs.semanticscholar.org/cfc8/3d2a1480f8c2009538a722390a58679b3f6b.pdf	80 mg 2 times / day multiple, oral dose: 80 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SELPERCATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12.7 h EXPERIMENT https://pdfs.semanticscholar.org/cfc8/3d2a1480f8c2009538a722390a58679b3f6b.pdf	160 mg 2 times / day multiple, oral dose: 160 mg route of administration: Oral experiment type: MULTIPLE co-administered:		SELPERCATINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
32 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	160 mg 2 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SELPERCATINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf	160 mg 2 times / day steady-state, oral dose: 160 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		SELPERCATINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Sample Use Guides

In Vivo Use Guide

Less than 50 kg: 120 mg; 50 kg or greater: 160 mg. Take it orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:59:49 GMT 2025` Edited by `admin` on `Wed Apr 02 09:59:49 GMT 2025`
Record UNII	CEGM9YBNGD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

6-(2-Hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]pyrazolo[1,5-a]pyridine-3-carbonitrile

Preferred Name

English

Selpercatinib

Official Name

English

LOXO-292

Code

English

SELPERCATINIB [JAN]

Common Name

English

SELPERCATINIB [MI]

Common Name

English

SELPERCATINIB [USAN]

Common Name

English

SELPERCATINIB [ORANGE BOOK]

Common Name

English

RET INHIBITOR LOXO-292

Common Name

English

RETEVMO

Brand Name

English

Selpercatinib [WHO-DD]

Common Name

English

LY-3527723

Code

English

LY3527723

Code

English

Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]-

Systematic Name

English

selpercatinib [INN]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/18/2071